NCT03696212 2021-02-21Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC AdenocarcinomaArrys TherapeuticsPhase 1/2 Terminated18 enrolled